SAB Biotherapeutics Warrant
SABSW
10 hedge funds and large institutions have $42.6K invested in SAB Biotherapeutics Warrant in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 0 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
11% more funds holding
Funds holding: 9 → 10 (+1)
0.18% more ownership
Funds ownership: 2.51% → 2.69% (+0.18%)
54% less capital invested
Capital invested by funds: $93K → $42.6K (-$50.5K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$8.97K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$1.75K |
| 3 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$605 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$5.66K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LP
1
LMR Partners
London,
United Kingdom
| $16.3K | – | – | – |
|
|
SCM
2
Shaolin Capital Management
Miami,
Florida
| $11.2K | -$5.66K | -94,076 | -20% |
|
|
3
Morgan Stanley
New York
| $9K | +$8.97K | +148,939 | +100% |
|
|
YCM
4
Yakira Capital Management
Westport,
Connecticut
| $3.27K | – | – | – |
|
|
5
UBS Group
Zurich,
Switzerland
| $872 | +$1.75K | +29,080 | New |
|
6
Walleye Capital
New York
| $702 | – | – | – |
|
|
WAM
7
Wolverine Asset Management
Chicago,
Illinois
| $688 | +$605 | +10,045 | +79% |
|
8
Walleye Trading
New York
| $468 | – | – | – |
|
|
NA
9
NewEdge Advisors
New Orleans,
Louisiana
| $32 | – | – | – |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $1 | – | – | – |
|
SABSW Hedge Fund Activity: Q4 2023 in Review
10 of the 6,863 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics Warrant (SABSW) for Q4 2023, worth a combined $42.6K — down 54% from $93K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new SABSW positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $8.97K. The largest seller was Shaolin Capital Management, cutting an estimated $5.66K.
- 10 institutional investors held SAB Biotherapeutics Warrant (SABSW) as of Q4 2023, up from 9 in Q3 2023.
- Funds reported $42.6K of SAB Biotherapeutics Warrant stock for Q4 2023, down 54% quarter-over-quarter.
- 1 fund opened new SAB Biotherapeutics Warrant positions in Q4 2023 and 0 closed out, a net change of +1 holder.
- The largest SAB Biotherapeutics Warrant buyer in Q4 2023 was Morgan Stanley, an estimated $8.97K added.
- The largest SAB Biotherapeutics Warrant seller in Q4 2023 was Shaolin Capital Management, an estimated $5.66K sold.
Based on aggregated 13F filings for Q4 2023.